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Transdermal Drug Delivery (TDD) through skin patches has many advantages including 
the following: slow and continuous administration of the therapeutic over long periods of 
time, timely dosage, accessibility, kinetic maneuverability, elimination of the “First Pass 
Effect” and negative side effects on the digestive tract. All of the above justify investment 
into further development of TDD therapies, despite the skin permeability restrictions posed 
on size and charge by the skin. As skin permeability varies between all individuals based 
on age, ethnicity and lifestyle, the determination of the proper drug dosages to be contained 
in the skin patch is highly reliant on clinical trials. The objective of this research is to 
further investigate the application of components of a modified Duda-Zalinsky Equation 
(DZE) for drug diffusivity through a polymer matrix, to account for physical enhancers 
added to the Heated Lidocaine-Tetracaine Patch based on diffusivity results obtained from 
tests run in a Franz Cell apparatus. Pre-clinical trials computational estimation of the drug’s 
diffusion properties with respect to the polymer matrix and skin will provide for safer 
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The focus of this research is to examine a computational method for estimating the 
diffusivity of a drug diffusing through a polymer matrix, such as that found in a skin patch 
with additional physical diffusion enhancers. Components of a modified Duda-Zalinsky 
Equation (DZE) [1] for molecular diffusivity through a polymer matrix will be considered 
to assess the impact of a heat enhancement. The physical enhancement incorporated into 
the Synera Heated Lidocaine/Tetracaine patch (a local anesthetic manufactured by Galen 
Inc.) is considered within this context. The energy and viscosity values obtained 
computationally will be compared with diffusivity results obtained from tests performed 
on the patch in a Franz-Cell apparatus [2-10]. Such pre-clinical trials and computational 
analysis of the diffusion characteristics of the drug will allow for proper dosage of the skin 
patches, thereby reducing the risk involved in clinical trials.      
 
1.2 Skin Anatomy 
The skin is the largest organ in the human body, with the primary purpose of preventing 
the entrance of foreign invaders. Additionally, the skin serves as a tool for body 
temperature adjustment and for sensory purposes. The skin’s three primary layers are, from 
top to bottom, the epidermis, dermis and hypodermis that mainly contains subcutaneous 
fatty tissue (Figure 1.1). The cells that make up the skin are called keratinocytes, due to 
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their increased production of the protein keratin that protects these epithelial cells from 
damage due to exterior stresses [11]. 
 
 
The epidermis consists of the stratum corneum (SC), a pigment layer and at the 
interface with the stratum basale of the dermis – the stratum spinosum. The stratum 
spinosum consists of basal cells that interlock with the dermal papilla that stick out of the 
stratum basale. Sweat pores that allow for water evaporation for body temperature 
mediation can be found on the surface of the SC. Sweat glands are located in the 
hypodermis, but are connected to the sweat pores and extend through all skin layers. The 
hair shaft extends out of the SC from the hair follicle that extends into the hypodermis, 
with the papilla of the hair located in the hypodermis. Each hair follicle contains sebaceous 
glands on its side, which secrete oil into the hair follicle in order to prevent the hair shaft 
from becoming brittle [11].  
 The skin performs several sensory functions. The dermis holds nerve endings closer 
to the interface of the epidermis and the dermis and extend into the hypodermis, thus giving 
them sensitivity to touch on the surface of the skin. The Pacinian corpuscles are nerve 
receptors embedded in the hypodermis and detect pressure and vibration. Arrector pili 
Figure 1.1 Skin anatomy with a close up of the SC and drug diffusion paths in the inset. 
"Human Skin Anatomy Diagram." Human Anatomy Body Picture.  
Benita S. Submicron Emulsions in Drug Targeting and Delivery.  
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muscles attached to the hair follicles are controlled by the sympathetic nervous system to 
contract and further insulate the skin, which causes rising of the hair shaft. Dispersed nerve 
endings extending throughout skin layers, blood and lymph vessels (located in the 
hypodermis) and hair follicles serve to detect and amplify sensory response [11].  
 This research is primarily focused on the SC, as it is the rate limiting step in TDD 
diffusion. As can be seen in the inset in Figure 1.1, the SC has a “brick and mortar” 
infrastructure. This brick-like characteristic is due to the ordering of the corneocytes that 
are linked via corneodesmosones, while the mortar-like characteristic is due to the lipid 
medium in between the corneocytes. Corneocytes are “dead” keratinocytes that are filled 
with keratin and engulfed in a cornified envelope of lipids and surrounded by a lipid filler. 
This foundation of the SC allows for only two paths for drug diffusion: directly through 
the corneocytes and lipids or solely through the surrounding lipid paths. These conditions 
provide both charge and size restrictions on the penetrant. In order to diffuse through the 
SC, the drug must be neutral and must abide by the “500 Da Rule”. The “500 Da Rule” is 
primarily based on clinical results and analysis of natural skin penetrants, which show that 
only molecular compounds or drugs with molecular weight less than 500 g/mol can freely 
diffuse through the SC [14].            
 
1.3 TDD Market 
The TDD market was valued at approximately $27 billion in 2013 and was predicted to 
experience an 8% Compound Annual Growth Rate (CAGR) for the five years following 
the publication of this report [16]. Local anesthetic patches have undergone several 
upgrades over the years, despite their constituting only 2% of the global TDD market 
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(Figure 1.2) [17]. Part of the interest in investment into local pain relief patches is to control 
usage of such therapeutics as they are controlled substances that may cause addiction. 




 Targeted drug delivery and sustained release drugs (Figure 1.3) are shown in the 
bar graph for market value of oral drugs. Sustained release drugs do not solely represent 
skin patches, which explains the increased value of the market sector, compared to the 
value reported in the previous paragraph. The key growth trends, observed in this depiction, 
between 2004-2011 are: a 2.5x increase for transmucosal drug delivery, a 5x increase for 
targeted drug delivery and a 1.8x increase for sustained release, implants and TDD. The 






















TDD GLOBAL PRODUCT SALES BY SEGMENT
Figure 1.2 Global TDDS sales by segment. 
B. Debjit, S. Duraivel, and K. P. .Sampath Kumar. "Recent Trends in Challenges and Opportunities in 
Transdermal Drug Delivery System." The Pharma  Innovation 1.10 (2012): 9-23. Web.  
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targeted drug delivery. This drastic difference is due to several factors. First, targeted drug 
delivery technologies experienced a significant breakthrough between the years 2006-
2011, before which sustained release, implants and TDD dominated the therapeutics 
market as its primary constituent. Second, sustained release, implants and TDD still 
encompass almost half of the therapeutics market. Third, many targeted drug delivery 
technologies utilize TDD and sustained drug release. Therefore, the extreme increase could 
be due to intermarket overlap. The increase in market value of transmucosal therapies does 
not signify a potential profit. The drug market percentage represented by transmucosal 






Figure 1.3 Drug delivery market trends. 
S. Kumar, K. P., D. Bhowmik, B. Chiranjib, and R. M. Chandira. "Transdermal Drug Delivery System - 
A Novel Drug Delivery System and Its Market Scope and Opportunities." International Journal of 




1.4 Advantages of TDD 
Transdermal drug delivery has a slow and continuous drug release profile. This sort of 
profile is ideal for treatments involving drugs with a short half-life that must be 
administered frequently over long periods of time. The patch’s constant presence also 




 The skin’s large surface area makes skin patches a highly accessible, yet non-
invasive and kinetically maneuverable form of treatment. As can be seen in Figure 1.4, oral 
and bolus drug administration involve fluctuations of the drug concentration in the blood, 
with a spike at the time of administration and a sudden decrease at peak concentration. In 
order to obtain an average dosage around the middle of the therapeutic range, the initial 
dosage must be much higher. Each valley-to-valley segment of Figure 1.4 represents a 
single administration. From this representation, it is evident that such treatment involves 
cyclical dosage fluctuations whose range varies between individuals based on weight, age, 
life-style and genetics. Therefore, for different individuals, the valleys and peaks of the 
Figure 1.4 Cycle of blood concentration with respect to time in TDD. 
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drug administration may exceed or fall below the toxic and minimal therapeutic drug 
concentrations, respectively [19].  
The oral/bolus forms of drug administration set up a precedent where a patient is at 
risk or is not receiving effective treatment at a certain fixed time, which can also bring 
upon a set of side effects such as nausea. In contrast, the skin patch maintains a quite 
consistent dosage that can be tailored by modification of the polymer matrix through which 
the drug diffuses. Application time of the patch is determined based on the point at which 
the drug remaining in the patch reservoir provides for the determined margin of decrease 
in resulting blood concentration. Furthermore, administration can be instantaneously halted 
via patch removal in the case of evident deleterious side effects.  
 
 
The ability of the skin patch to circumvent passage through the gastrointestinal tract 
(GIT) has two advantages: 1) the drug does not damage the GIT or its mucus membrane 
and 2) the “First Pass Effect” is eliminated. The “First Pass Effect” (Figure 1.5) is a result 
of the body’s clearance system. After entering the stomach, the drug may be detected and 
cleared out by the body as a foreign object in passage through the intestines and the liver, 
resulting in a reduced dose entering the blood stream where the drug undergoes another 
Figure 1.5 Illustration of the “First Pass Effect”. 
"First Pass and Plasma Drug Levels (Introduction) (Human Drug Metabolism)." Whatwhenhow RSS. 
Web. 03 Feb. 2016.  
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series of clearance. This requires that the initial dosage administered to the patient be much 
higher than the therapeutic dosage. As the amount of drug cleared out varies between 
individuals, as mentioned above, this may result in varying side effects that cannot be 
halted without complete clearance that is physiologically controlled [20].  
 
1.5 Limitations of TDD 
The skin’s foundation is built on preventing the entrance of any foreign objects into the 
body. As such, the charge and size limitations, discussed in the skin anatomy section, 
eliminate the design of skin patches for a large scope of therapeutics, including: gene 
therapy, liposomal drug delivery and charged particles. As an individual’s lifestyle impacts 
metabolic activity, while SC thickness and skin composition varies in different parts of the 
body and between individuals, the theoretical blood dosage with respect to polymer matrix 
design varies between individuals and is highly reliant on clinical trials. As a result, skin 
patch dosages are determined based on clinical trial results and thus pose high risk to the 
subject as the resulting dosage may fall in an individual’s toxic dosage. Finally, skin 














2.1 Basic Skin Patch Construct 
The two primary types of skin patches are: the reservoir patch and the matrix patch (Figures 
2.1 and 2.2, respectively). The main difference between these types of patches is their form 
of drug storage and kinetics. The patch acts as an initial drug reservoir. Once the patch is 
placed at the site of application, the drug begins to diffuse into the SC due to osmotic 
pressure and forms a secondary reservoir in the SC, which further emphasizes the SC’s rate 
limiting property. The drug diffuses through the SC into capillaries, present in the 







Figure 2.1 Cross-section through a reservoir patch. 
Margetts L. and Sawyer R. "Transdermal Drug Delivery: Principles and Opioid Therapy." Contin Educ 
Anaesth Crit Care Pain Continuing Education in Anaesthesia, Critical Care & Pain 7.5 (2007): 171-76.  
Figure 2.2 Cross-section through a matrix patch [23]. 
Margetts L. and Sawyer R. "Transdermal Drug Delivery: Principles and Opioid Therapy." Contin Educ 
Anaesth Crit Care Pain Continuing Education in Anaesthesia, Critical Care & Pain 7.5 (2007): 171-76.  
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The reservoir patch contains the drug in liquid form in a reservoir on top of a 
polymer membrane interface, which acts as the rate limiting component of drug release 
from the patch itself. This feature allows for greater control of the drug delivery rate by 
varying the polymer membrane composition, conformation and constituents. Despite the 
increased control over the diffusion rate, an initial burst of the drug may occur due to the 
large concentration difference between the drug reservoir and SC as the SC initially has 
yet to form its own drug reservoir. Furthermore, any inconsistency in the polymer 
membrane thickness may pose as a site of increased diffusion rate that may cause an 
overdose. In the matrix patch, the drug is evenly distributed in the adhesive polymer matrix, 
with the drug diffusion rate limiting factors being the amount of drug held in the polymer 
matrix, the formulation of the polymer matrix and the area of the patch applied to the skin 
[23].   
 
2.2 Governing Diffusion Equations 
Diffusion involves the movement of particles from regions of high concentration to regions 
of low concentration via random movement. Diffusion whose driving force is solely the 
concentration gradient between regions in the volume of diffusion is referred to as passive 
diffusion, with the movement of the diffusing particles following the “Random Walk” 
model or probability function. This type of diffusion is quite slow with a well-defined 
direction. In some cases, where diffusion must occur faster or against a concentration 
gradient (i.e., to trigger another process), a convective factor is added to the diffusion in 
the form of additional energy or physical barriers. In 1855, Adolf Fick derived the most 







 The flux J represents the amount of particles diffusing through a cross sectional 
area perpendicular to the path of diffusion. Fick’s First Law of Diffusion provides 
information on the expected amount of flux. Figure 2.3 shows that the flux is proportional 
to the diffusivity of the particle, D, which accounts for the tendency of the particle to diffuse 
through the medium. The concentration gradient, dC/dx, generates the energy that causes 
the particles to diffuse from areas of high concentration to areas of low concentration. The 
negative sign in equation (2.1) signifies the increase in flux in the direction of decreasing 














 Fick’s Second Law of Diffusion (equation (2.2)) provides information regarding 
the rate of change of concentration at any point in space. The left side of the equation, the 
gradient of the concentration with respect to time, is directly related to the Laplacian of the 




 Figure 2.4 depicts this relationship in which the flux approaches zero with 
increasing distance from the cross sectional area being analyzed, regardless of the distance 
being in front or behind the cross sectional area. As the distance to the cross sectional area, 
perpendicular to the path of diffusion, approaches zero from the positive direction, the flux 
Figure 2.4 Fick’s 2nd Law plotted in terms of the flux with respect to the distance from 
the cross sectional area perpendicular to the path of diffusion.  
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goes to infinity. Conversely, as the distance to the cross sectional area, being discussed, is 
reduced in magnitude from the negative direction, the flux approaches negative infinity 
[24]. 
Steady-state diffusion is diffusion that is not time dependent. In contrast, 
nonsteady-state diffusion is time dependent and exhibits varying diffusion profiles at 
varying time points. Fick’s second law of diffusion is primarily used for nonsteady-state 
diffusion profiles as it contains a time dependent term. In analysis of steady-state diffusion, 
the gradient of concentration with respect to time term is equal to zero. 
  
2.3 Diffusion Through Skin 
In order for diffusion to be feasible and predictable in a noninvasive manner, the drug’s 
diffusivity needs to be estimated. The simplest calculation for molecular diffusivity is given 
by the Stokesian Diffusion, in which a spherical particle with radius r diffuses through a 
continuous fluid medium (equation (2.3)). The numerator of the Stokes-Einstein equation 
accounts for the positive contribution due to particle diffusion in terms of absolute 
temperature (T) and the Boltzmann constant (k), whereas the denominator emphasizes that 
increasing particle size (r) and viscosity (µ) poses a hindrance for diffusion. The viscosity 
plays a significant role because each individual particle gets engulfed by a static layer of 
the fluid medium. This results in a friction between the static layer and the fluid medium 







Aside from the direct temperature correlation seen in equation 2.3, there is a hidden 
exponential temperature factor that contributes to the particle diffusivity that is hidden in 
the temperature dependence of viscosity. Evidence of this dependence is visible in  
equation (2.4), Joback’s equation for viscosity, which correlates the liquid dynamic 
viscosity (µL, units: Pa·s) to the sum of constant viscosity factors per bond group in the 
molecule (µa and µb) and the temperature (T). The division of bond segments in the 
molecule refers to carboxyl bonds, double bonds, bonds that are part of an aromatic ring 
etc. This equation is valid between the melting temperature of the molecule and 0.7 times 
its critical temperature, i.e., the temperature at which the gas form of the molecule can no 
longer condense back into solution [25]. Viscosity decreases with temperature 
exponentially because more molecules obtain sufficient energy to overcome the resistive 
shearing forces that hinder diffusion or movement. Also, greater particle mobility results 
in a higher level of disorder that thins out the liquid. The Stokes-Einstein diffusivity does 
not consider particle shape; it contains two particle size factors – the radius in the 
denominator and the molecular weight in the viscosity calculation.  
 




 More often than not, the geometry of the particle diffusing or the nature of the 
medium results in Non-Stokesian Diffusion. Large particles that are arranged in chains or 
complex geometries, i.e., polymers, proteins etc., may change geometry as a result of the 
attractive forces between the medium and side groups, may have their center of gravity in 
a nonsymmetrical position along their length and may diffuse in different directions. This 
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results in more complex diffusion patterns that are dependent on the available free 
volume/holes that can accommodate the movement, geometry and molecular properties of 
the diffusing particles with respect to their matrix.    
As the polymer membrane through which the drug active diffuses in the patch is 
not a fluid, the Stokes-Einstein parameters are breached. Furthermore, the cell membrane 
exhibits anisotropic diffusion/penetration properties. The fluid in the plane of the 
membrane results in transverse particle diffusion through the fluid. In one form of diffusion 
through the SC, lateral diffusion or transmembrane diffusion, the diffusing particle is set 
back by the hydrocarbon chains that are vertically anchored. In the second form of diffusion 
through the SC matrix (around the corneocytes), there are physical hindrances that lead to 
loss of energy to the particle and results in a smaller diffusivity. The “brick and mortar” 
structure of the SC prevents transmembrane diffusion and facilitates increased diffusion 
path length. Therefore, in both processes of diffusion through the skin patch membrane and 
the skin, the diffusion of the drug is Non-Stokesian [25].  
Non-Stokesian diffusivity computations vary based on diffusion characteristics. 
They normally involve adding an exponential multiplier to the Stokes-Einstein equation 
that accounts for the system’s deviation from Stokesian Diffusion. In the case of particles 
diffusing through a polymer membrane and the SC, analysis via the free volume theory is 
most adequate. This analysis involves an exponential factor that is a probability function 
that computes the probability of the diffusant encountering a hole with the minimum 
critical volume required for diffusion to occur. In this view, the particle and the hole are 
viewed as mutually diffusing.  
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Experiments performed to assess free hole volume in a hydrocarbon chain matrix, 
which can be compared to the hydrocarbon tails of the cell membrane, showed that 
approximately 35% of the total volume is attributed to free hole volume [26]. It is not 
feasible to computationally calculate the exact free hole volume in a polymer matrix as it 
accounts for the difference between the total volume of the matrix and the Van der Waals 
volume of the polymers, which may vary with time as well. Therefore, the free hole volume 
should be statistically based on the following premises: 1) it is most probable to encounter 
small holes and 2) the formation of large holes is highly improbable. Thus, the diffusion 
coefficient depends on the number of holes, the net hole formation frequency and the 
probability of finding a hole as a function of the exponent of the ratio of the minimum hole 
volume necessary for diffusion with respect to the average hole volume [25].    
 
 ⁄ ∗⁄  
 
(2.5) 
     
 The basic probability function for diffusion through a polymer matrix is that posed 
by Vrentas and Dudas for the infinite particle diffusivity, as can be seen in equation (2.5). 
The term D0 refers to the Stokes-Einstein diffusivity (equation (2.3)). The first exponential 
term accounts for the Arrhenius factor of the diffusion that is related to the kinetic energy 
of the diffusing particle. This E term refers to the activation energy required for the drug 
to overcome the attractive intermolecular forces with its medium in order to diffuse. T 
refers to the temperature in Kelvin and k is the Boltzmann constant. The second exponential 
term accounts for the ratio of the critical jumping volume required for diffusion with 
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respect to the total available free volume (V*/V) multiplied by the ratio of the solvent to 
polymer jumping unit that is determined by a factor of the occupied volume of the diffusing 
molecule (subscript 1) and the polymer matrix (subscript 2) [1].  Table 2.1 emphasizes the 
role of the shape of the diffusing molecule. It is evident that, for molecules of equal 
volumes, the elongated molecules have a greater diffusivity. This phenomena is attributed 
to the higher probability of the longer configuration of the molecule finding a hole that fits 
its smaller cross section (the cross sectional area perpendicular to its length). This 
directional diffusion property is referred to as reputation [25]. 
 







Table 2.1 Effect of the Shape of a Diffusing Molecule on Diffusion in a Polymer  
Stein, Wilfred D., and W. R. Lieb. Transport and Diffusion across Cell Membranes. Orlando: 
Academic, 1986, 94-102. 
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2.4 TDD Penetration Enhancement Technologies 
The purpose of investment into TDD penetration enhancement technologies is to improve 
drug diffusion and to facilitate the utilization of TDD for a wider range of drugs, including 
those that violate the charge and size barriers posed by the SC. The two categories of these 
technologies are: physical penetration enhancers and physical methods of TDD. Physical 
penetration enhancers include modifications to the SC to increase its permeability or its 
electrochemical character, including: Iontophoresis, Electroporation and 
Ultrasound/Sonophoresis. Physical methods of TDD involve a more forceful 
circumvention of the SC that might involve its local elimination; such methods include: 
Hypodermic Needles, Jet Injections, Crystal Microdermabrasion, Thermal Ablasion, Laser 
Ablasion and Microneedles [27].  
 A schematic of the construct of an iontophoretic system is shown in Fig. 2.5. The 
system involved contains two electrodes that are in contact with the skin and extend out of 
electrolyte chambers. One electrolyte chamber contains the drug along with anions (if the 
drug is cationic, as in the figure), while the other chamber contains a buffer solution of 
similar polarity.  
 
 
Figure 2.5 Depiction of an Iontophoretic electroosmotic system on the ionic level. 
Bhowmik, D., Duraivel, S. and Sampath Kumar, K.P. "Recent Trends in Challenges and Opportunities 
in Transdermal Drug Delivery System." The Pharma Innovation 1.10 (2012): 9-23. 
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A small electric current passing through the electrodes causes an electrical potential 
across the skin. As this functions as an electroosmotic system, the solvent flows in the 
direction of the ion movement and transports the cationic drug molecules through the skin. 
The dosage results from the magnitude of the charge generated by the applied current. This 
method generates better diffusion outcomes with cationic drugs because the cell membrane 
potential is negative, with increase in cationic drug contribution to electroosmosis being 
directly proportional to the molecular weight of the drug.  However, the skin’s 
permselectivity can be modified via adjustment to the formulation’s pH, thereby promoting 
diffusion in the direction of the anions and allowing this method to be applied to anionic 
drugs as well. Additionally, increased ion mobility is preferable for decreased period of 
current passage, as the electrolytes “compete” to a certain extent with the active agent as 
charge carriers [28]. 
 Despite osmosis generally being a passive form of diffusion, iontophoresis involves 
convective diffusion as the therapeutics are repelled into the skin. This property results in 
additional functions such as physiological monitoring by attraction of water soluble 
molecules present in the interstitial fluid. Drug dosages can be fine-tuned to provide for 
pulsatile drug delivery profiles that may prevent the body from becoming tolerant to the 
therapeutic [27]. Iontophoresis requires strict current limitation to prevent erythema. This 
method is not cost effective and was recalled by the European Medicine Agency due to 
continuous fentanyl release resulting from corrosion products from the system components  
when the device was deactivated, as well [22].  
 In electroporation, high voltage pulses are applied for a short duration to 
specifically increase SC permeability in controlled areas, thereby increasing the possible 
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diffusant size. The high-voltage electrical pulses disrupt the brick-and-mortar structure of 
the SC, which physically increases its susceptibility for diffusion while causing 
electrophoretic movement of the diffusing particles. This method provides promising in 
vitro result when compared to other permeability enhancers, but in vivo skin toxicological 
studies have yet to be sufficiently surveyed [22].  
  Ultrasound/Sonophoresis involves application of low frequency ultrasound to a 
site of the SC to increase the percutaneous drug flux. The SC’s infrastructure is interrupted 
with the formation of cavitational bubbles by the ultrasound’s oscillations. Sonication 
devices can include additional features, such as real-time impedance feedback that provides 
control over the activation of sonication with respect to the relevant conductance level. 
Despite the ability to individually tailor this form of enhancement, it is not widely used as 
its effect in humans is not sufficiently clear [22]. 
 Hypodermic Needles that extend directly into the dermis are one of the most 
commonly used physical methods of TDD, with the feature of delivering impermeating 
and unstable compounds. This is achievable because the hypodermic needle acts as a piston 
that applies quickly a high pressure force that administers a large bollus of the drug, at an 
instant [29]. The controlled and continuous drug release that is desirable in TDD systems 
can be obtained by placing indwelling catheters in the skin. This method perforates the 
skin, thus making it invasive and a site of infection. In concept, Jet Injections are similar 
to hypodermic needles as they use high-pressure accelerators that utilize helium to push 
through either solid or liquid particles through the skin in a piston action. The advantage 
of jet injections over hypodermic needles lies in their noninvasive property, but they cannot 
facilitate long term drug release.  Microscale microneedles are also used in a similar 
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manner, but they are designed short enough to avoid excitation of nerve endings while 
penetrating through the SC. Solid microneedles are used prior to the application of a skin 
patch, as the holes created result in skin permeability increasing by four orders of 
magnitude. Coating of the microneedles with the therapeutic allows for direct delivery of 
the drug upon penetration of the microneedles [27].  
 
 
 Crystal microdermabrasion is a form of pretreatment to skin patch application. As 
part of the local preparation for application of the patch, the skin is exfoliated by 
microcrystals blown unto it. This treatment removes the CS, which has been shown to 
successfully increase the net flux and diffusivity of low-molecular weight drugs through 
the skin. Microdermabrasion is selectively designed to remove the SC only, while leaving 
the rest of the epidermis layer intact [27]. 
 Laser ablation involves shining laser beams unto the skin to create pores through 
the SC that facilitate the diffusion of drugs that violate the charge and to some extent size 
limitations on TDD. This form of diffusion enhancement may also serve to extract 
Figure 2.6 Sketch of different types of microneedles and their application. 
Wang, Binghe, Longqin Hu, and Teruna Siahaan. Drug Delivery: Principles and Applications. 2nd ed. 
Wiley, 2005. Print. p. 217  
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physiological data from the patient, by drawing interstitial fluid from the pores created in 
the SC. As laser ablation is a high-cost and complicated technology and this form of 
treatment is not for a single use, it is not widely used. This form of enhancement is not 
always performed a single time because the SC grows back and must be removed for 
subsequent patch therapies, which shows the advantageous minimally destructive character 
of this form of enhancement [22].  
 Thermal ablation works on the same premise as laser ablation, which is selective 
removal of the SC without causing permanent damage to the skin and its infrastructure. 
Heat is applied to the skin by an external heat source for a short amount of time, which 
disrupts and removes the SC and creates microchannel structures in the skin. The resulting 
microchannel structures are caused by three processes that occur as a result of the sharp 
heat exposure: (1) the loss of the structural viability of the brick-and-mortar structure of 
the SC; (2) the disruption of the keratin network within the SC; (3) the decomposition and 
vaporization of keratin due to heat, which leaves behind microscale vacancies in the SC 
[30].  
It has been shown that the SC permeability is significantly increased with 
increasing temperature during thermal ablation, rather than with heating time. This being 
the case, there must be a strict control over the balance between effective temperature levels 
and exposure time of the tissue below the SC to prevent permanent damage to the skin. Lee 
et al. (2011) devised an apparatus to locally heat the skin for a duration of the order of 100 
µs. This apparatus consists of water in a microchamber that is rapidly heated by discharging 
electric current through it. By utilizing the conversion of electrical current to thermal and 
mechanical energy in a localized manner, the generated jet of superheated steam is 
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immediately ejected unto the skin. In order to validate the effectiveness and safety of this 
construct, the authors [30] sought out to: (1) determine the heat transfer profile through the 
skin to produce a protocol with the most effective and safe heat level with respect to 
exposure time; (2) evaluate the efficacy of the microdevice in removing the SC, so as to 
improve skin permeability to hydrophilic molecules and macromolecules [30].  
Thermal ablation was performed at a temperature of 1100 °C and tested for 1 µs, 
10 µs, 100 µs, 1 ms, 10 ms and 100 ms time durations. Thermal ablation was tested for 
three levels of skin exposure: bare skin, skin covered by a heat conducting mask and skin 
covered by a heat conducting mask covered by a window patterned insulating mask. The 
skin exposed under latter conditions creates a perforated pattern on the SC, thereby 
showing precision of localization of the thermal ablation process while leaving segments 
of viable SC between the pores that can prevent infection and damage to future 
development of the skin. The 100 µs ablation time provided for the best combination of 
skin viability and increased permeability. The tested skin exhibited an increase of four and 
three orders of magnitude in permeability to sulforhodamine and bovine serum albumin 
(BSA), respectively [30].  
Thermal ablation is a more economically favorable and safe method compared to 
the other diffusion enhancement techniques, while significantly improving drug diffusion 
and the breadth of drugs that may be used for TDD. It has been observed that properly 
combining more than one enhancement technique may generate a synergistic effect, 
pending the treatment or therapeutic characteristics. Combining electroporation with 
sonophoresis results in two different types of disruptions to the SC structure 
simultaneously, while electroporation also adds to electroporetic diffusion of the drug. 
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When electroporation is combined with iontophoresis, the electroporation increases SC 
permeability while iontophoresis adds a convective diffusion force to the diffusing 
particles. A similar effect occurs when iontophoresis is combined with microneedle 
treatments that provide direct access to the vascularized skin layers [22].  
 
2.5 Impact of Heat on Diffusion 
As was discussed in Section 2.3, equation (2.3) for particle diffusivity in a Stokesian system 
experiences its temperature impact primarily from the viscosity term that exponentially 
decreases with increasing temperature. This reduction in viscosity is primarily attributed 
to increased particle energy and reduced molecular organization due to the addition of heat 
to the system. As such, the Stokesian system’s activation energy is determined based on 
the activation energy for the viscosity of the medium, which is determined by the increase 
in free volume due to expansion with increasing temperature [25]. 
 In a Non-Stokesian system, the increase in diffusivity with respect to temperature 
is two-fold, resulting from: the increase in free volume and the increase in the overall rate 
of formation of holes.  This is expressed in equation (2.5), for the probability function 
based diffusivity, in the exponential factor of the viscosity in the Stokesian diffusivity term 
and in the exponential Arrhenius term. Furthermore, activation energy in diffusion through 
a polymer matrix is greater than in diffusion through a liquid. Therefore, the temperature 
contribution to the diffusivity for a Non-Stokesian system is of greater value. As can be 
seen in Table 2.2, the type of polymer through which the particle is diffusing greatly 
impacts the activation energy of the diffusing particle. As natural rubber is not galvanized, 
the polymer strands slide past each other when undergoing tensile stress and allow for more 
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open diffusion paths. On the other hand, polyisobutylene is a crosslinked butyl rubber that 
makes it very resilient. This type of infrastructure contains more restricted diffusion paths, 






2.6 Impact of Heat on Skin Permeability 
In TDD, the drug crosses two diffusion membranes: the polymer matrix in the patch and 
the SC with two different fluxes that are related to each other by the partition coefficient 
of the aqueous solution of the drug in the reservoir with respect to the SC. Once the drug 
partitions from the reservoir to the SC, it also partitions into the deeper levels of the skin 
that can be termed aqueous, as well (Figure 2.7).   
Table 2.2 Activation Energy for Diffusion within Polymers 
Stein, Wilfred D., and W. R. Lieb. Transport and Diffusion across Cell Membranes. Orlando: 
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 The flux of the drug diffusing from the reservoir to the deeper skin levels is related 
to the product of the SC permeability (P) and the area (A) through which the drug is 
diffusing (first part of equation (2.7)). As with previous flux calculations, this one is 
proportional to negative concentration gradient (Caq,1 and Caq,2). The second form of the 
flux equation substitutes the SC permeability for the ratio of the SC diffusivity (DSC) and 
the diffusion path length (L). As can be seen from equation (2.6) for the partition coefficient 
Figure 2.7 Simplified model of diffusion starting from the patch reservoir, across the 
polymer matrix and SC*.  
* The dimensions of the SC are exaggerated compared to the skin patch reservoir. 
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of the SC, Km, the concentrations on the surface of the membranes on the aqueous sides 
are related to the concentrations on the SC side of the membranes (CSC,1 and CSC,2). This 
relationship is equivalent to the ratio of the solubility of the diffusant in the SC medium 
with respect to the aqueous medium at each of the separating barriers. Therefore, by 
substituting the SC partition coefficient relationship into the second part of equation (2.7), 
the final form of the flux equation with respect to the concentrations in the aqueous regions 
is obtained. This form of the flux equation holds the advantage of requiring the aqueous 
concentrations, which are easily obtained compared to the concentrations in the SC [25].  
 From equation (2.8), it is evident that any modifications to the SC permeability are 
related to the diffusivity across the SC. Permeability is a rate phenomenon that contains 
contributions from partitioning and intermembrane diffusion. The diffusivity through the 
SC follows Non-Stokesian behavior, as the SC is not fluid. Diffusion through the SC is 
similar in concept to diffusion through a polymer matrix, but its permeability varies 
between individuals based on genetics, temperature, lifestyle and body part. Therefore, 
temperature impacts SC permeability both from the Stokesian diffusion diffusivity term 
and the exponential Arrhenius term. An increase in temperature results in an increase in 
SC permeability and drug solubility because there is an increase in free volume and its 
formation. This is also expressed in the lipid fluidization or melting around the corneocytes, 







2.7 Case Studies – Supporting Research 
At this point, computational diffusion studies of TDD are quite scarce. Most research and 
testing on skin patches relies on clinical trials including those for dosage determination, 
which poses high risk to the test subjects. The TDD clinical trial reports primarily rely on 
questionnaire data collected from the subject and their respective blood tests. This poses 
several issues in obtaining an exact analysis of any skin patch that is released into the 
market, as skin permeability and individual sensitivity to drug uptake varies between 
individuals. As skin permeability is quite variable and side effects are possible, clinical 
trials cannot be completely eliminated but they can be designed in a safer manner by 
computational estimation of the drug’s diffusivity. Three case studies will be discussed. 
The first Nicotine patch analysis is qualitatively based on clinical trials, whereas the second 
research will discuss the computational determination of the diffusivity of nicotine 
diffusing through the skin patch copolymer matrix. Finally, the clinical trial report for the 
SYNERA Heated Lidocaine Tetracaine patch will be discussed, as it is the patch being 
tested in this study.     
2.7.1 Nicotine Patch 
As mentioned above, most pharmacokinetic analyses of TDD patches are rarely 
quantitative. One such analysis was used to compare the diffusion profile of the 21-mg/24-
hour NiQuitin Patch (Nicoderm CQ in the USA and Nicabate in Australia) with that of the 
Nicorette Invisi 25-mg/16-hour patch. The test subject pool consisted of fifty smokers that 
smoke 11-40 cigarettes daily, twenty one female and twenty nine males. The NiQuitin 
patch is applied for twenty four hours, with an initial dose of 21 mg. The Nicorette Invisi 
patch is prescribed for sixteen hours of application, with a starting dose of 25 mg. The 
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subjects received both forms of treatment consecutively, with half of the subjects starting 
with the NiQuitin treatment followed by the Nicorette treatment while the other twenty five 
subjects went through the treatments in the reverse order. The control was the NiQuitin 
patch worn for sixteen hours rather than the prescribed twenty four hours. The 
pharmacokinetic profile for the TDD treatments was obtained from blood samples drawn 
from the patients up to thirty two hours post-initiation of treatment. All patient incidents 
were reported via a questionnaire [32].  
 
 
The results indicated that the NiQuitin Patch provided the larger overall nicotine 
exposure, as indicated by its larger area under the curve (AUC) in Figure 2.8. Also, the 
maximum plasma nicotine concentration was higher for the NiQuitin patch and was 
reached faster than for the Nicorette patch, which exhibited a more gradual nicotine release 
profile without the initial concentration spike seen for the NiQuitin patch. Most patients 
Figure 2.8 Mean plasma nicotine concentrations during exposure to the NiQuitin and 
Nicorette Invisi transdermal Nicotine systems. 
Deveaugh-Geiss, Angela M., L. H. Chen, M. L. Kotler, L. R. Ramsay and M. J. Durcan. 
"Pharmacokinetic Comparison of Two Nicotine Transdermal Systems, a 21-mg/24-hour Patch and a 25-
mg/16-hour Patch: A Randomized, Open-label, Single-dose, Two-way Crossover Study in Adult 
Smokers." Clinical Therapeutics 32.6 (2010): 1140-148.  
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reported adverse events for both treatments. The adverse events were classified as primarily 
mild, as they were attributed to irritation due to the patch itself and some dizziness, with 
one subject requiring cessation of treatment. It was not mentioned which of the treatments 
led to the latter case nor did the article indicate if it was the patient’s first or second round 
of TDD treatment. Individual variation in response to medication exemplifies the need to 
computationally analyze TDD treatments prior to clinical trials. Furthermore, the 
diffusivity differences between both patches were neither extensively analyzed nor were 
they calculated for the initial increase in nicotine plasma concentration for both patches. 
Computational analysis of the diffusivity through the polymer matrix for both patches 
could put into perspective the significance of their individual design parameters and their 
implications [32]. 
 
2.7.2 Computational Determination of Diffusivity 
The article New Screening Methodology for Selection of Polymeric Matrices for 
Transdermal Drug Delivery Devices [1] is the only research directed at the computational 
analysis of a drug diffusing through a polymer matrix in the skin patch. In this case, the 
nicotine patch was used to validate the results. The methodology in this research is the 
basis for the research discussed in this thesis, except that the skin patch analyzed is the 
SYNERA local anesthetic heated lidocaine-tetracaine patch. As this skin patch contains a 
diffusion enhancing component and there are two diffusing molecules, some adjustments 
will be made to the modified Duda-Zalinsky equation (DZE) constructed by Falcone in his 
computational analysis of the diffusivity of nicotine [1].  
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Diffusion through the TDD patch can be modeled as diffusion through a planar 
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In equation (2.7), C is the solute concentration, D is the diffusivity, t is the time, x 
is the diffusion length. The relationship in equation (2.8) for the ratio of the solute 
concentration (Mt) at time t with respect to the initial concentration M∞ holds true for the 
following boundary condition: concentration at time t is equal to or less than half the initial 
concentration [1].  
 For the purpose of analysis of a drug diffusing through a polymer matrix, the 
diffusion process must be modeled by the free volume theory. This model describes 
diffusion as a mechanical model that involves concurrent exchange between the free and 
occupied volumes. Therefore, the specific gap free volume in equation 2.5 is calculated 
based on the ratio of the molar gap free volume ( ) with respect to the molecular 
contribution of each of the constituents (the ratio of the individual weight fractions, wi, 









Equation (2.9) was incorporated into Vrenta and Duda’s equation (equation (2.5)) 
to form equation (2.10). Since in the nicotine patch, nicotine diffuses through a block 
copolymer matrix, the second weight fraction in the denominator of equation (2.9) is 
multiplied by the ratio of the weight fraction of each of the polymers in the matrix divided 
by their molecular weight. Furthermore, the effect of the copolymer matrix was carried 
over to the calculation of the solvent critical molar volume jumping unit with respect to the 
polymer jumping unit that is designated as ε (eq. (2.11)) [1]. 
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One of the advantages of this methodology lies in the usage of the hydrodynamic 
radius of the drug, as the critical volume for diffusion relies on the resulting effective 
volume due to the rotation of the molecule about its center of gravity. The molecule’s 
effective center of rotation does not necessarily lie at the center of the molecule and can be 
impacted by secondary interactions of the molecule’s functional groups. The 
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hydrodynamic radius (R0) is obtained by relating the spherical molar volume of the drug 
and its density, which should give an over estimation of the actual molar volume of the 
drug as it is representative of the radius that stems from the rotation of the molecules 
(equation (2.12)). Energy values were obtained through the Tonge and Gilbert equation. 
 Diffusivity values, obtained for nicotine, based on these computation were 
compared to diffusivity values obtained from the concentration profile of the investigated 
nicotine patch. The concentration profile for the nicotine patch was generated from UV 
spectrophotometry absorption readings of samples extracted periodically from a Franz-Cell 
apparatus, which had the nicotine patch clamped to its cell top opening thereby permitting 
nicotine diffusion (Figure 2.9) [1].  
 
 
As can be seen in the results in Figure 2.10, below the calculations for the 
cumulative amount released, the product of the diffusivity and the time point in the 
diffusion process, for both experimental and calculated values are close with the percent 
error increasing with respect to the diffusion time. The final diffusivity results, summarized 
in Table 2.3, show that the calculated diffusivity is of the same order of magnitude as the 
experimental diffusivity, with an over estimation of approximately 17%. To emphasize the 
significance of this result, the diffusivity values obtained were compared to the diffusivity 




values for nicotine provided in the literature, which stated that the diffusivity range is 
between 10-9-10-10 cm2/s. Therefore, this computational model is fitting to describe 







 The method of computation of diffusivity, used for nicotine, is the basis for the 
procedure used in the research discussed in this thesis. In this research, Galen 
Figure 2.10 Cumulative release comparison for the experimental and estimated 
nicotine diffusivity values. 
Falcone, R., Jaffe, M. and Ravindra, N.M., New screening methodology for selection of polymeric 
matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and Nanobiomaterials, Volume 
2 Issue BBN2, p. 65-75, 2013. 
Table 2.3 Comparison between experimental and calculated nicotine diffusivity 
values 
Falcone, R., Jaffe, M. and Ravindra, N.M., New screening methodology for selection of polymeric 
matrices for transdermal drug delivery devices, Bioinspired, Biomimetic and Nanobiomaterials, 
Volume 2 Issue BBN2, p. 65-75, 2013. 
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Pharmaceitical’s Heated Lidocaine/Tetracaine local anesthetic patch is analyzed, with 
added corrections to the diffusivity equation proposed by Falcone so as to account for the 
impact of the diffusion enhancement on the diffusivity of the solutes.   
2.7.3 SYNERA Heated Lidocaine-Tetracaine Patch 
Lidocaine has been used for topical anesthesia since the 1980’s in various forms. It has 
evolved over several cycles from a cream to a TDD patch where the lidocaine active is held 
as part of a eutectic mixture. Some of the hallmarks of the development of this local 
anesthetic include the following forms: cream in the form of a submicron emulsion (SME), 
lidocaine/prilocaine eutectic mixture in regular cream, lidocaine/tetracaine eutectic 
mixture in regular cream, lidocaine/tetrcaine eutectic mixture in SME cream, 
lidocaine/epinephrine patch (Iontocaine,1995), lidocaine patch (Lidoderm, 1999), 
lidocaine/ultrasound patch (SonoPrep, 2004) and finally, lidocaine/tetracaine heated patch 
(Synera, 2005 – the gold standard). 
 Eutectic mixtures are normally mixtures of two components that together develop 
different physicochemical properties compared to their separate pure forms, which is due 
to moderate molecular interactions between the individual constituents. These properties 
do not impact the individual constituents’ inherent molecular orientation, rather some of 
their characteristics are modified. As an example, the eutectic mixture’s melting point is 
significantly lower than either constituent’s individual melting point, which poses the 
advantage of lowering the processing temperature of either of the constituents if called for.  
 In the case of the lidocaine/prilocaine eutectic mixture, the melting point of the 
system is 32°C while lidocaine’s melting point in its pure form is 68°C. As this melting 
point is slightly below skin surface temperature, the lidocaine anesthetic assumes a molten 
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form upon contact with the skin. The eutectic mixture’s physical properties facilitate more 
rapid skin penetration of lidocaine with respect to its pure form. Therefore, eutectic 
mixtures have been found to enhance transmembrane diffusion.  
 In the past, the lidocaine anesthetic cream has been formulated as a eutectic mixture 
with prilocaine; but studies have shown to exhibit competitive diffusion properties. 
Lidocaine’s diffusion is more influenced by the partition process, whereas prilocaine’s 
diffusion is more influenced by the transport process. A diffusion study of the 
lidocaine/prilocaine eutectic mixture showed that maximum skin permeation occurs for 
mixture compositions where the solid and liquid phase are not at equilibrium. This is 
indicative of questionable stability of the eutectic mixture formulation.  
 The latter observation was corroborated by a thermal analysis that compared the 
stability of the lidocaine/prilocaine eutectic mixture with the stability of the 
lidocaine/tetracaine eutectic mixture. The authors found that the lidocaine/tetracaine 
eutectic mixture’s crystallization peaks, observed through modulated temperature 
differential scanning calorimetry (MTDSC), are in close temperature proximity to the 
lidocaine/prilocaine eutectic mixture’s crystallization peaks. This implies that the 
lidocaine/tetracaine eutectic mixture contains more intermolecular interacting groups, 
thereby preventing crystallization out of formulation of either constituent in the binary 
mixture. It is evident from the molecular structures of lidocaine and tetracaine (Figure 2.11) 
that both molecules have the same functional groups with some structural differences and 







The Synera heated patch (Figure 2.12) was compared in a clinical trial setting to 
the lidocaine/prilocaine cream (EMLA). The Synera patch contains a eutectic mixture of 
70 mg of lidocaine and 70 mg of tetracaine, with a suggested application time of at least 
twenty minutes – preferably thirty minutes, prior to local procedure. The lidocaine 
prilocaine cream provides with a 25 mg/mL dosage and should be applied one hour prior 
to local procedure. The Synera patch contains an iron nanoparticle and carbon heating pod 
on the top layer of the patch that is covered by a perforated covering, which exposes the 
heating pod to oxygen upon opening of the packaging and induces an exothermic oxidation 
of the iron nanoparticles that locally raises the skin surface temperature by 5°C.  As 
previously discussed, the added heating component provides additional energy to the 
diffusing particles as well as promotes fluidization of the lipid matrix in the SC that could 
explain the shorter anesthetic application time.  






The investigation study group consisted of 82 healthy adults (37 males, 45 females) 
with varying skin types that received both anesthetic treatments simultaneously in two 
separate, but equivalent, skin locations. Both anesthetics were applied for 10, 20, 30 and 
60 minutes prior to a vascular access procedure. Pain intensity was assessed by the subjects 
using a 100 mm visual analogue scale (VAS), with skin or any other side effects being 
visually inspected. The reported median VAS score was significantly lower for the Synera 
patch compared to the lidocaine/prilocaine cream for all time points leading up to thirty 
minutes; yet similar VAS scores were given to both anesthetics at the 60 minutes time 
point. Overall, it was deduced that the Synera lidocaine/tetracaine patch is more effective 
than the lidocaine/prilocaine cream due to it faster penetration. It is important to emphasize 
the significance of a computational model for this type of investigation, as opinion based 
pain evaluations are very individual because different people have different pain thresholds 
Figure 2.12 Layer by layer breakdown of the Synera heated lidocaine/tetracaine heated 
patch. 
Sawyer, J., S. Febbraro, S. Masud, M. A. Ashburn, and J. C. Campbell. "Heated Lidocaine/tetracaine 
Patch (SyneraTM, RapydanTM) Compared with Lidocaine/prilocaine Cream (EMLA(R)) for Topical 
Anaesthesia before Vascular Access." British Journal of Anaesthesia 102.2 (2009): 210-15. 
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and tolerances. Therefore, as this comparison validates the advantages of the Synera patch, 
it is of purely qualitative value.  
Anesthetics have been shown to be of high skin penetration efficacy with skin 
fluidization properties. This is counterintuitive as anesthetics primarily perform their 
function by inhibiting protein-mediated transport processes that take part in the body’s 
signaling process. Yet further investigation elucidated that, in addition to the anesthetic’s 
inhibitory character, it also behaves similarly to a plasticizer in a polymer. Plasticizers are 
small molecules that disrupt intermolecular interactions in polymers, thus reducing 
polymer brittleness and increasing its ductility with respect to a certain temperature. In 
effect, this change in physical properties results from the reduction in the glass transition 
temperature of the polymer. Therefore, plasticizers serve to increase diffusion rates in 
polymers. Similarly, at high concentrations, anesthetics actually increase membrane 
permeability. Anasthetics fluidize lipid bilayers and biological membranes, which signifies 
that the Synera heated lidocaine/tetracaine patch has an additional inherent diffusion and 
permeability enhancer upon SC saturation. Despite anesthetic potency being an 
equilibrium phenomenon that relies on anesthetic partitioning, membrane permeability is 











3.1 Impact of Heat/Composition 
Computational research in this area has focused on the standard skin patch, to utilize a 
modified version of the DZE to predict drug diffusion in a noninvasive manner prior to 
testing of patches. It is of great importance to validate these modifications for other 
formulations of patches with varying matrices, drug actives and especially diffusion and 
permeability enhancers. Diffusion and permeability enhancements are of significant value 
for future formulations, as they will not only improve the diffusion efficiency of the drug, 
but will also provide an opportunity for the utilization of TDD to a wider range of 
therapeutics. As discussed extensively in the previous chapter, the heat enhancement in the 
Synera patch adds energy for partitioning of both lidocaine and tetracaine and it helps to 
fluidize the SC by liquefying the lipid components in the polymer matrix and facilitating 
less resistive diffusion paths. Furthermore, the Synera patch involves a eutectic mixture as 
its active component as opposed to a single drug active. 
 The free hole volume is a function of the structure of the polymer matrix and 
diffusant occupying volume in relation to the reference temperature relative to the glass 
transition temperature. Equation (3.1) shows Fierro et al.’s method of computing the free 
volume. 
 




K11 and K21 are free volume parameters for the active components, which can be retrieved 
via nonlinear regression of the equation for the base ten logarithm of the difference in 
viscosity between the glass transition and reference temperatures [35]. K12 and K22 are the 
free volume parameters for the polymer matrix. T is the reference temperature and wi and 
Tgi are the weight fractions and glass transition temperatures of component “i”, where the 
subscript 1 denotes the drug active and 2 denotes the polymer matrix. It is important to 
note in this equation that only one active at a time is included in this calculation. This is 
acceptable because the diffusion of drug actives is not codependent [1].  
K11, K21 and K12, K22 are related to the Williams-Landel-Ferry (WLF) constants, 
C1, C2. K12 is related to the critical molar volume and the overlap factor. In combination 
with a nonlinear regression with respect to the Doolittle equation for viscosity, K12, can be 
used to solve for the overlap factor. The WLF constants for the polymer were retrieved 
from linear regression of values found in the literature for varying PVA concentrations 
[36]. The glass transition temperature for lidocaine and tetracaine was calculated by a 
group contribution method (equation (3.2)). This method computes the product of the 
molecular weight and “glass transition temperature” contributed by individual parts of the 
polymer backbone (denoted “i”) and side chains (denoted “j”), distributed over the entire 









3.1.1 Modifications to DZE 
The energy and viscosity components of the diffusivity calculations performed in this 
research are in agreement with those performed in the computational analysis of nicotine 
discussed in Section 2.7.2, with a few modifications. In this case, the solute is a binary 
system and the matrix is being treated as one polymer component. Furthermore, the 
temperature analysis will consider the additional 5°C added by the Synera skin patch 
heating component.  
 
3.1.2 Composition Calculations 
The composition of the drug actives was taken as 1:1 as listed in the specifications of the 
drug. Based on the list of ingredients of the patch, the primary polymer contribution to the 
diffusion membrane was attributed to polyvinyl alcohol. TGA was used to assess the 
weight contribution of the polymer matrix to the TDD patch system. Due to the proprietary 
nature and confidentiality of this patch, these results and analyses will not be discussed in 
this thesis.  
 
3.1.3 Energy Calculations 
The energy calculation was computed based on the Tonge and Gilbert computation, 
equation (3.1) [33]. To obtain the partitioning energy (E*) involved in either of the drugs’ 
diffusion through the polymer matrix, the cohesive energy density (δ) of lidocaine 
tetracaine was computed based on equation (3.2). The cohesive energy density is also 
representative of the constituent’s solubility. The enthalpy of vaporization (H), subtracted 
by the product of the ideal gas constant (R) and the temperature in kelvin (T), represents 
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the cohesive energy of the molecule that is stored in its own molecular volume unit (VM). 
The cohesive energy density for PVA was obtained from the literature. Equation (3.3) 
shows the Yamada and Gunn equation [34] for the molecular volume at the testing 
temperature, as the cohesive energy of the molecule varies with temperature. All properties 
denoted with the subscript “c” represent the critical properties of the molecule, at which 
point condensation of vapor does not occur despite temperature elevation.  
 
 ∗ 0.8988 ln log 2.8377	 (3.1) 
 
 





 1, 	 0.7 














 The saturated liquid molar volume requires the calculation of the acentric factor 
(equation (3.4)), a measure of corresponding state for saturated hydrocarbons [38]. All the 
properties denoted with the letter “r” refer to the reduced value of that property. This 
equation is only valid for the reduced saturated vapor pressure (prsat) at a reduced 
temperature value of 0.7. The Clausius Clapeyron equation (equation (3.5)) for real gases 
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was used to calculate the saturated vapor pressure. This calculation was based on the 
pressure and temperature data at room temperature from the literature. The ideal gas 
Clausius Clapeyron equation has an added correction factor, Z, called the compressibility 
factor. The compressibility factor was estimated with the Berthelot equation  




1. PermGear Franz-Cell apparatus (6-cell apparatus). 
 




1 11 1.5 
2 10.6 1.5875 
3 11.6 1.524 
4 12.6 1.60 
 
2. Hot water bath. 
3. Water pump. 
4. Synera skin patches. 
5. Saline solution. 
6. UV spectrophotometer. 
7. 500 mg/L lidocaine in water stock solution. 
8. 100 mg/L tetracaine in water stock solution. 




10. IR camera.  
For the experiments, a Franz cell apparatus was employed with a water pump for 
temperature control of the system. Saline served as the diffusion media in the cell body. As 
the patches were quite large, the clamp on its own was enough to keep the patch in place. 
Sample analysis was conducted via a UV spectrophotometer. Stock solutions prepared for 
the calibration curve were made of dilutions of 500mg/L lidocaine in de-ionized water and 
100mh/L tetracaine in de-ionized water solutions.  
 
3.3 Franz-Cell Apparatus 
The Franz-Cell was connected to a hot water pump to maintain the temperature of the 
system. The water flows between the outer walls of the cell, while the inner cell contains a 
small magnetic stirrer set underneath a coil to induce constant mixing when the apparatus 
is turned on. The Synera patch was clamped without a cap, as its dimensions permit this 
construct. The cell bodies should be filled completely with saline and must form a meniscus 
in the cell top, so as to ensure constant surface contact of the patch diffusion site and the 
aqueous solution. Periodic samples of approximately 1 mL were taken at four different 
time points through a long needle that extends into the cell body via an inlet opening. To 
prevent disruption of the diffusion system, an equivalent volume of saline was added into 
the cell body after each sample extraction.  
A calibration curve was set up from serial dilutions of the lidocaine and tetracaine 
stock solutions. 0.1 M hydrochloric acid was added to the stock solutions along with pH 
buffer no. 6, so as to promote solute dissolution. Based on literature values, the peak UV 
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absorbance wavelengths are 262±1nm [39] and 310±1nm [40] for lidocaine and tetracaine, 
respectively.  As Beer’s law states, for small absorbance values (between 0.01-1), the 
absorbance is linearly related to the sample concentration, diffusion length and extinction 
coefficient of the sample. Therefore, the linear regression equation obtained from the 
calibration curve for the stock solution and its dilutions provides a direct relationship to the 
active concentration in the sample. The diffusion profile for the drug is made up of a plot 
of the generated concentrations with respect to their sampling time. The concentration 
profile for a skin patch is linear until the concentration plateaus. The slope of the line prior 
to the leveling of the concentration is the diffusivity. For this wavelength range, quartz 
cuvettes must be used to obtain accurate readings. Table 3.2 lists the dilutions of the stock 
solutions, where C0 is a concentration of 100 mg/L. 
 
Lidocaine Concentration Tetracaine Concentration 
5 C0 500mg/L C0 100 mg/L 
3.25 C0 325 mg/L 0.9 C0 90 mg/L 
2.5 C0 250 mg/L 0.75 C0 75 mg/L 
1.75 C0 175 mg/L 0.5 C0 50 mg/L 
C0 100 mg/L 0.25 C0 25 mg/L 
0.75 C0 75 mg/L 0.10 C0 10 mg/L 
0.5 C0 50 mg/L   
0.25 C0 25 mg/L   




Table 3.2 Serial Dilution Concentrations for Lidocaine and Tetracaine’s Calibration 
47 
 
3.4 Temperature Corroboration 
Temperature corroboration in this experiment is important because it provides information 
on the functionality of the patch and the temperature stability of the diffusion system, 
whose temperature is maintained by the pumping of the water from the hot water bath. 
Thermocouples were placed between the cell body and its holder so as to record the 
temperature of the system. An IR camera is used to verify that the 5°C temperature increase 
reported by the manufacturer is accurate and persistent throughout drug administration. 
Based on the difference in the colometric temperature in the area of the patch compared to 
the temperature further down in the cell body, the induced temperature increase can be 
validated. As the SC is less than 3 µm in thickness, the temperature penetration depth is 


























RESULTS AND DISCUSSION 
 
4.1 Computational Results 
Table 4.1 shows the calculated hydrodynamic radius, the glass transition temperature and 
its corresponding viscosity for lidocaine and tetracaine. Table 4.2 is divided into three 
testing temperatures for lidocaine and tetracaine. As can be seen, tetracaine has a larger 
activation energy, due to its larger molecular weight. Initially, the impact of the heating 
pod was thought to have a large impact on the energy of the actives (Table 4.2). Based on 
the tabulated values with respect to temperature, the increase in additional available energy 
is not significant for such temperature differences.  
 
 
  Tg (K) µ (Pa-s) R0 
Lidocaine 219.74 0.05594947 3.9588E-10 
Tetracaine 268.105 0.013004086 3.9588E-10 
 
 
 The viscosity decreases with increasing temperature, but the results show that for 
all temperatures they are of the same order of magnitude. Therefore, their impact on the 




Table 4.1 Calculated Hydrodynamic Radius, Tg and the Corresponding Viscosity for 




  Property Lidocaine Tetracaine 
T=303.15 K E (J) 38678.63 43147.55 
µ (Pa-s) 0.003716002 0.00455435 
D0 (m/s^2) 1.50942E-06 1.03294E-06 
T=308.15 K E (J) 38713.12 43172.64 
µ (Pa-s) 0.003309274 0.003998203 
D0 (m/s^2) 1.7229E-06 1.19602E-06 
T=310.15 K E (J) 38726.97 43182.705 
µ (Pa-s) 0.003162641 0.003799714 
D0 (m/s^2) 1.81448E-06 1.26667E-06 
 
  Table 4.3 summarizes the WLF factors that are used to calculate the free volume 
parameters for the free volume. Lidocaine and tetracaine have similar critical molar 
volumes, which are less than a third of PVA’s critical volume. Therefore, it may be deduced 
that the primary contribution to the overlap factor and the primary occupier of the free 
volume is PVA. The diffusivity values obtained with the DZE will not be extensively 
discussed for this system, as they were off by about two orders of magnitude with respect 
to the experimental diffusivities. This is attributed to the free volume calculations that need 
further fine tuning.   
 
 
  C1 C2 V* (cm3) 
PVA 17.4 51.6 313.8 
Lidocaine 1.22534 3.69403 89.79595 
Tetracaine 1.7934 4.76435 94.26971 
 
 
Table 4.2 Energy, Viscosity, Free Volume and Stokes Einstein Diffusivity Multiplier 
for Lidocaine and Tetracaine with Respect to Temperature Setting 




4.2 Experimental Results 
In order to quantify the concentrations of the samples taken from the Franz Cell apparatus 
at different points in the diffusion process, a UV absorption calibration curve for different 
known concentrations of lidocaine was set up. Pure lidocaine and tetracaine exhibit peak 
absorbance values at wavelengths of 262±1 nm and 310±1 nm, respectively. In this 
particular UV spectrophotometer, the absorbance peaks were observed at 262.5 nm and 
310.5 nm for lidocaine and tetracaine, respectively.  
 
 
According to the Beer-Lambert law, for absorption values between 0.01-1 (i.e. low 
concentrations), there is a linear relationship between the concentration and absorbance 
(equation (4.1)). The absorbance is related to the sample concentration (C) multiplied by 
the extinction coefficient of the sample (ε) and the path length of the light passing through 
(L), which is simply the width of the cuvette (10 mm in this case). This relationship held 
true for the solution concentrations plotted in Figure 4.1, that display an R2 value for both 







































Figure 4.1 Lidocaine (left) and tetracaine (right) UV absorbance calibration curves. 
51 
 
 	 (4.1) 
 
       
 
 As can be seen in Figure 4.2, the temperature was held stable throughout the 
diffusion process, with mild decrease in the last ten minutes. As will be discussed below, 
by the end of the first 5-10 minutes (temperature pending) the drug concentration peak is 
reached and maintained through the end of the run. The IR images (Figure 4.3, 4.4) confirm 
that the company statement that the heating pod provides a local increase in temperature of 
5°C is correct.  







The side view (Figure 4.3) serves to show the heat diffusion distance, as there is a 
heat gradient throughout the length of the cell body where the maximum temperature is at 
Figure 4.3 Thermal image of cells 3 and 4* during the diffusion run (side view). 
* Cell 4 is the left cell and it is the nonheated control. 
Figure 4.4 Thermal image of cells 1-4* during the diffusion run (top view). 
* Cell 4 is the left cell and it is the nonheated control. 
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the top and the minimum is at the bottom. Despite this gradient it may be assumed that 
when the Synera patch is applied the local SC temperature matches the maximum 
temperature, which is the critical determinant of the drug penetration. Figure 4.4 confirms 
that the control did not experience the oxidation reaction as a result of obstructing the top 
openings with tape. The temperature difference was further confirmed by the color 
difference between the top view of the patch that was used as the control and the rest of the 
cells.    
Figure 4.4 below contains the lidocaine diffusion profile at 30°C, 35°C and 37°C. 
The diffusion with respect to time at 30°C reaches its peak cumulative release at after 10 
minutes, whereas this time period is shortened to 5 minutes for diffusion at 35°C and 37°C. 
At 30°C the control, the patch that did not undergo oxidation, exhibited a significantly 
reduced supplied dosage. Yet for the higher testing temperature, the peak concentration is 
similar with respect to the control. As can be seen in Figures 4.4A and 4.4B, the results 
collected for cell 3 peak at twice the lidocaine released, which compared to the rest of the 
cells. This is the reason that the tests results in Figure 4.4 C were only performed on the 
first two cells. The experiments in Figures 4.4A and 4.4B were performed on the same day 
and the discrepancy was correlated to a faster spin rate of the magnet in cell 4, which 
initially went unnoticed.  A research conducted on the Franz Cell apparatus showed that 
stirring speed impacts the amount of time a dye gets dispersed in the Franz cell and the 
time it takes it to reach up the sampling arm. On the other hand, too high of a stirring speed 






Figure 4.5 displays the mass of accumulated tetracaine in the cell body. A similar 
diffusion pattern to that of the lidocaine was observed, with peak accumulation occurring 
at the 10 minutes and 5 minutes time point for 30°C and 35-37°C, respectively. The same 
discrepancy with respect to cell 4 was observed in the tetracaine results, as well. It is 
important to note that despite the initial lidocaine and tetracaine dosages being identical in 
the patch regimen, approximately double the amount of lidocaine compared to tetracaine 








































































Figure 4.4 Cumulative accumulation of lidocaine with respect to time at 
A)30°C=303.15 K, B) 35°C=308.15 K and C) 37°C=310.15 K. 
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ratio of 182 at pH 7.3 compared to tetracaine’s higher partition ratio of 5370 at pH 7.3 [42]. 
As the cell media is saline, 0.9% NaCl aqueous solution in water, tetracaine’s hydrophobic 
character results in a hindered diffusion of tetracaine. The Synera patch prescribing 
information discussed its clinical trials that revealed that approximately 1.7 mg and 1.6 mg 
of lidocaine and tetracaine, respectively, were absorbed by the subject [43]. The mass of 
lidocaine was substantially below the maximum dose released in the Franz cell, which can 
be explained by the skin barrier that is posed by the skin. In contrast, the reported peak 
accumulation for tetracaine was slightly higher than the experimental results in Figure 4.5 
C. This may be attributed to tetracaine’s higher partition ratio that compensates for its 
reduced diffusion into aqueous solution, by increasing its probability of diffusing through 


































































Figure 4.5 Cumulative accumulation of tetracaine with respect to time at 













30°C 1 5.50208e-07 3.68461e-09 
 2 6.30504e-07 3.96706e-09 
 3 9.65049e-07 5.88052e-09 
 4, Control 1.87482e-07 7.84265e-10 
35°C 1 9.48895e-07 5.73027e-09 
 2 1.18473e-06 7.30005e-09 
 3 2.70498e-06 2.648e-08 
 4, Control 1.30702e-06 7.73061e-09 
37°C Cell 1 6.53372e-07 4.44946e-09 
 Cell 2 6.16912e-07 5.75549e-09 
 1, Control 9.8185e-07 8.57112e-09 
 
 




T (°C) Lidocaine Tetracaine Lidocaine Tetracaine 
30 5.67775e-08 2e-10 3.9432 0.732185 
35 1.66763e-07 1.11e-09 3.5457 0.692926 
37 2.57814e-08 9.24e-10 1.9292 0.530981 
 
 Table 4.4 shows that the diffusivity of lidocaine is greater than that of tetracaine by 
two order of magnitude, as the cell medium is aqueous. As can be seen in Table 4.5, the 
standard deviation between cell 1 and cell 2 is insignificant. Therefore, diffusion results 
for these cells may be regarded as consistent duplicates for the purpose of analysis. 
Comparison of the diffusivity results with respect to the control showed that the added heat 
enhanced diffusion below 35°C. Above this temperature, diffusivity values in the Franz 
Cell apparatus were not enhanced (Table 4.6). This may be attributed to the eutectic 
Table 4.4 Franz Cell Diffuivity Results 
 




mixture’s melting point, which is 32°C. As room temperature is approximately 25°C, it is 
deduced that the heating components ensures that the eutectic mixture is at an optimal 
diffusion state, liquid, upon application of the patch. Although normal body temperature 
suffices to melt the eutectic mixture, the passive heat transfer would take longer without 











30 1.87482E-07 5.90356E-07 68.24% 
35 1.30702E-06 1.06681E-06 -22.52% 
37 9.8185E-07 6.35142E-07 -54.59% 








30 7.84265E-10 3.82584E-09 79.50% 
35 7.73061E-09 6.51516E-09 -18.66% 















Table 4.6 Comparative Analysis of the Average Diffusivity of Lidocaine (top) and 






The results showed that the temperature increase did not have a strong impact on the 
diffusive properties of lidocaine and tetracaine through the polymer membrane. Rather, the 
added temperature serves to facilitate better skin penetration by adjusting skin permeability 
and the physical state of the eutectic mixture. Further research is crucial for further 
specification and broadening of patch applications to include therapeutics that have charge 
or are larger than 500 Da. Such therapeutics include liposomal drug delivery, magnetic 
nanoparticle assisted drug delivery and gene therapy. Converting these treatments into 
TDD patches will not only alleviate the experience involved with these treatments, but it 
will help to improve their efficacy due to the sustained release feature of the skin patch. 
This pre-clinical trial, utilizing a scientific approach via computational analysis, serves as 













COMPARISON OF THE CUMULATIVE ACCUMULATION WITH RESPECT 
TO THE DIFFUSION CONTROL 
  
The following table shows that the difference in diffusivity is negligible above 30°C 
because the melting point of the eutectic mixture is 32°C. The percent difference in 
accumulation, with respect to the control, for lidocaine and tracaine correspond to each 








Table A.1 Comparative Analysis of the Average Accumulation of Lidocaine (top) and 






1. Falcone, R.,  Jaffe, M. and Ravindra, N.M., New screening methodology for  
selection of polymeric matrices for transdermal drug delivery devices,  
Bioinspired, Biomimetic and Nanobiomaterials, Volume 2 Issue BBN2, p.  
65-75, 2013 
 
2. FDA guideline for scale up and post approval changes (SUPAC) for in vitro release  
testing and in vivo, UCM 070930. Silver Spring: US Federal Drug and  
Admnistration, 1997, 23–28.  
 
3. Kailas, T. D. and Chern W.H.. "Development and Validation of In Vitro  
Release Tests for Semisolid Dosage Forms-Case Study." Dissolution  
Technol. Dissolution Technologies 10.2 (2003): 10-15. Web.  
 
4. Martin, S., Dressman J., Brown C. and Shah V.. "FIP/AAPS  
Guidelines for Dissolution/In Vitro Release Testing of Novel/Special  
Dosage Forms*." Dissolution Technol. Dissolution Technologies 10.1  
(2003): 6-15. Web. 
  
5. Raney, S. G., Lehman, P. A. and Franz, T. J. In Vitro - In Vivo Correlation (IVIVC)  
of Percutaneous Absorption Through Human Skin. AAPS 2010 Poster  
Presentation (Cetero Research). New Orleans: American Association of  
Pharmaceutical Scientists, 2010.  
 
6. Marangon, A., Bock, U. and Haltner, E.  
http://www. acrossbarriers.de/uploads/media/FCT08_SUPAC_SS.pdf. 
 
7. Lionberger, R. FDA Pharmaceutical Equivalence of Topical Dosage Forms  
Presentation. Silver Spring: US Federal Drug and Admnistration, 2005.  
 
8. Flynn, G. L., Shah, V. P., Tenjarla, S. N., Corbo, M., DeMagistris, D., Feldman, T.  
G., Franz, T. J. and Miran, D. R. Assessment of value and applications of  
in vitro testing of topical dermatological drug products. Pharmaceutical  
Research 16(9), 1325. 
 
9. Hauck, W., Shah, V.P., Shaw, S.W. and Ueda, C.T. "Reliability and  
Reproducibility of Vertical Diffusion Cells for Determining Release Rates  
from Semisolid Dosage Forms." Pharm Res Pharmaceutical Research  
24.11 (2007): 2018-024. Web.  
 
10.  Addicks, W. J., Flynn, G. L., Weiner, N. and Chiang, C. -M. Drug Transport from  
thin applications of topical dosage forms: development of methodology.  




11. Benita, S. Submicron Emulsions in Drug Targeting and Delivery.  
Amsterdam: Harwood Academic, 1998. Print.  
 
12. "Human Skin Anatomy Diagram." Human Anatomy Body Picture.  
 
13. Brannon, H., MD. "Stratum Corneum Anatomy - The Key to Healthy,  
Attractive Skin." About.com Health. 4 Nov. 2009. Web.  
<http://dermatology.about.com/od/anatomy/ss/sc_anatomy.htm>.  
 
14. Bos, J.D., Marcus, M.H. and Meinardi M.. "The 500 Dalton Rule for the Skin  
Penetration of Chemical Compounds and Drugs." Experimental  
Dermatology Exp Dermatol 9.3 (2000): 165-69.  
 
15. Pond, S.M., and Tozer T.N.. "First-Pass Elimination." Clinical  
Pharmacokinetics 9.1 (1984): 1-25. Web.  
 
16. Gagliardi, M.. Global Markets and Technologies for Thin-Film Batteries.  
Rep. no. FCB036A. BCC Research. Aug. 2013. Web.  
<http://www.bccresearch.com/market-research/fuel-cell-and-battery- 
technologies/thin-film-batteries-fcb036a.html>  Executive Summary  
 
17. Bhowmik, D., Duraivel, S. and Sampath Kumar, K.P. "Recent Trends in  
Challenges and Opportunities in Transdermal Drug Delivery System." The  
Pharma Innovation 1.10 (2012): 9-23. Web.  
<http://www.thepharmajournal.com/vol1Issue10/Issue_dec_2012/2.1.pdf> 
 
18. Sampath Kumar, K.P., Bhowmik, D., Chiranjib, B. and Chandira, R. M.  
"Transdermal Drug Delivery System - A Novel Drug Delivery System and  
Its Market Scope and Opportunities." International Journal of Pharma and  
Bio Sciences 1.2 (2010): 1-21. Web.  
 
19. Bolognia J., Jorizzo, J.L. and Schaffer, J.V. Dermatology. 3rd ed.  




20. Pond, S.M. and Tozer, T.N. "First-Pass Elimination." Clinical  
Pharmacokinetics 9.1 (1984): 1-25. Web.  
 
21. "First Pass and Plasma Drug Levels (Introduction) (Human Drug Metabolism)."  
Whatwhenhow RSS. Web. 03 Feb. 2016.  
 
22. Paudel, K.S., Milewski, M., Swadley, C.L., Brogden, N.K., Ghosh, P. and  
Stinchcomb, A. L. "Challenges and Opportunities in Dermal/transdermal  




23. Margetts, L. and Sawyer, R. "Transdermal Drug Delivery: Principles and  
Opioid Therapy." Contin Educ Anaesth Crit Care Pain Continuing  
Education in Anaesthesia, Critical Care & Pain 7.5 (2007): 171-76. Web.  
 
24. Crank, J., The Mathematics of Diffusion. 2nd ed. Oxford: Clarendon, 1975,  
1-14.  
 
25. Stein, W.D. and Lieb, W. R.. Transport and Diffusion across Cell  
Membranes. Orlando: Academic, 1986, 94-102. 
 
26. "Joback Method." Project Gutenberg Self-Publishing Portal. World Heritage  
Encyclopedia. Web.  
<http://central.gutenberg.org/articles/Joback_method>.  
 
27. Bondi, A. "Free Volumes and Free Rotation in Simple Liquids and Liquid  
Saturated Hydrocarbons." The Journal of Physical Chemistry J. Phys.  
Chem. 58.11 (1954): 929-39. 
 
28. Naik, A., Kalia, Y.N. and Guy, R.H. "Transdermal Drug Delivery: Overcoming  
the Skin’s Barrier Function." Pharmaceutical Science & Technology  
Today 3.9 (2000): 318-26. Web.  
 
29. Rawat, S., Vengurlekar, S., Rakesh, B., Jain, S. and Srikarti, G. 
"Transdermal Delivery by Iontophoresis." Indian Journal of  
Pharmaceutical Sciences Indian J Pharm Sci 70.1 (2008): 5. Print.  
 
30. Binghe, W., Hu, L. and Siahaan, T.. Drug Delivery: Principles and  
Applications. Print.  
 
31. Lee, J.W., Priya, G., Park, J.H., Allen, M.G. and Prausnitz, M.R. "Microsecond  
Thermal Ablation of Skin for Transdermal Drug Delivery." Journal of  
Controlled Release 154.1 (2011): 58-68. Web.  
 
32. Vizserálek, G., Tamás, B., Takács-Novák, K. and Sinkó, B. "PAMPA Study of  
the Temperature Effect on Permeability." European Journal of  
Pharmaceutical Sciences 53 (2014): 45-49. Print.  
 
33. Deveaugh-Geiss, A.M., Chen, L.H., Kotler, M.L., Ramsay, L.R., and Durcan M.J.  
"Pharmacokinetic Comparison of Two Nicotine Transdermal Systems, a  
21-mg/24-hour Patch and a 25-mg/16-hour Patch: A Randomized, Open- 
label, Single-dose, Two-way Crossover Study in Adult Smokers." Clinical  
Therapeutics 32.6 (2010): 1140-148.  
 
34. Tonge, M.P. and Gilbert, R.G. "Testing Models for Penetrant Diffusion in  




35. Yamada, T. and Gunn, R.D.. "Saturated Liquid Molar Volumes.  
Rackett Equation." Journal of Chemical & Engineering Data J. Chem.  
Eng. Data 18.2 (1973): 234-36. Web.  
 
36. Mendieta-Taboada, O., Sobral, P.J., Carvalho, R.A. and Habitante, A.M.B.  
"Thermomechanical Properties of Biodegradable Films Based on Blends  
of Gelatin and Poly(vinyl Alcohol)." Food Hydrocolloids 22.8 (2008):  
1485-492. Web.  
 
37. Camacho-Zuñiga, C. and Ruiz-Treviño, F.A. "A New Group Contribution  
Scheme To Estimate the Glass Transition Temperature for Polymers and  
Diluents." Industrial & Engineering Chemistry Research Ind. Eng. Chem.  
Res. 42.7 (2003): 1530-534. Web.   
 
38. "Poly(vinylalcohol)." Polymer Data Base. 2015. Web.  
<http://polymerdatabase.com/polymers/polyvinylalcohol.html> 
 
39. Pitzer, K.S. "The Volumetric and Thermodynamic Properties of Fluids. I.  
Theoretical Basis and Virial Coefficients 1." J. Am. Chem. Soc. Journal of  
the American Chemical Society 77.13 (1955): 3427-433. Web.  
 
40. Kumar, B. K., Rajan, V. and Begum, N.T. "Analytical Method Development  
and Validation of Lidocaine in Ointment Formulation by U.V  
Spectrophotometric Method." International Journal of Pharmacy and  
Pharmaceutical Sciences 4.2 (2012): 610-14. Web.  
 
41. Bempong, D. K. "USP Monographs: Tetracaine." USP Monographs: Tetracaine.  
US Pharmacopeia.  
<http://www.pharmacopeia.cn/v29240/usp29nf24s0_m81550.html> 
 
42. Ng, S.F., Rouse, J.J., Sanderson, F.D., Meidan, V. and Eccleston, G.M.  
"Validation of a Static Franz Diffusion Cell System for In Vitro  
Permeation Studies." AAPS PharmSciTech 11.3 (2010): 1432-441. Web.  
 
43. Galen Pharmaceuticals. Synera (Lidocaine and Tetracaine) Topical Patch  
Prescribing Information. Souderton, PA: Galen Pharmaceuticals, 2013.  
Print.  
 
 
